Boehringer Ingelheim Completed Major Investment for Respiratory Diseases

| By | Boehringer Ingelheim, Respimat, Respiratory diseases

Just as the next-generation Respimat® inhaler hits the first European markets, Boehringer Ingelheim has completed the investment of €105 million to expand associated production operations at its sites in Dortmund and Ingelheim. Sufficient capacity is now available for the next generation of this successful medical device. 

Differing from other application systems for inhaler-based therapies, Respimat® produces a soft, slow-moving and long-lasting mist which allows a high percentage of the active ingredient to be deposited deep in the lungs. The new Respimat® has the same well-established features, but is now even more user-friendly, reusable and consequently better for the environment.

“The volume of the investment and further development of Respimat® demonstrate Boehringer Ingelheim’s long-term commitment to combating serious respiratory diseases. This also underscores our commitment to Germany as a production location,”

explains Country Manager Dr. Sabine Nikolaus.

Additional production space for another flexible assembly line was set up in Dortmund for the new Respimat®. Of the total investment, €78 million went towards this development and production site, while the remaining €27 million was invested in Ingelheim for purchasing new machinery, equipment, and materials for an additional packaging line. These two sites work hand-in-hand, meaning that the entire development and manufacturing process is carried out exclusively in Germany, making Boehringer Ingelheim unique in this respect.

Boehringer Ingelheim has been working to improve the lives of patients with respiratory diseases for more than a century. The main areas of focus include chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, idiopathic pulmonary fibrosis, scleroderma-related interstitial lung disease and other forms of progressive fibrosing interstitial lung diseases.